With 0.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.76 whereas the lowest price it dropped to was $2.41. The 52-week range on BOLD shows that it touched its highest point at $15.24 and its lowest point at $2.19 during that stretch. It currently has a 1-year price target of $16.33.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BOLD was up-trending over the past week, with a rise of 4.55%, but this was up by 0.80% over a month. Three-month performance dropped to -16.78% while six-month performance fell -34.79%. A look at the trailing 12-month EPS for BOLD yields -2.75 with Next year EPS estimates of -3.46. For the next quarter, that number is -0.76. This implies an EPS growth rate of 83.91% for this year and 47.04% for next year.
Float and Shares Shorts:
At present, 22.25 million BOLD shares are outstanding with a float of 14.17 million shares on hand for trading. On 2024-12-31, short shares totaled 0.28 million, which was 124.0 higher than short shares on 1732838400. In addition to Dr. Jonathan E. Lim M.D. as the firm’s Co-Founder & Independent Chairman, Mr. Zachary Hornby serves as its CEO, President & Director.
Institutional Ownership:
Through their ownership of 0.7592 of BOLD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BOLD reported revenue of $0.0 and operating income of -$18715000.0. The EBITDA in the recently reported quarter was -$18453000.0 and diluted EPS was -$0.74.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With BOLD analysts setting a high price target of 15.0 and a low target of 14.0, the average target price over the next 12 months is 14.5. Based on these targets, BOLD could surge 492.89% to reach the target high and rise by 453.36% to reach the target low. Reaching the average price target will result in a growth of 473.12% from current levels.
Analysts have provided yearly estimates in a range of -$6.45753 being high and -$6.62747 being low. For BOLD, this leads to a yearly average estimate of -$6.5425. Based on analyst estimates, the high estimate for the next quarter is -$0.76 and the low estimate is -$0.78. The average estimate for the next quarter is thus -$0.77.
